basdeals.blogg.se

This antiinflammatory action of angiotensin II receptor antagonists may contribute to their beneficial cardiovascular effects.Ītherosclerosis is now widely accepted as a chronic vascular inflammatory disorder that is present in a variety of conditions such as hypertension and diabetes mellitus. In contrast, addition of pravastatin led to a significant ( P<0.001) reduction in LDL cholesterol serum concentrations in the olmesartan and placebo treatment groups (−15.1% and −12.1%, respectively).Ĭonclusions- Angiotensin II receptor blockade significantly reduces vascular microinflammation in patients with essential hypertension by as early as week 6 of therapy. After 12 weeks of therapy, high-sensitivity C-reactive protein (−21.1% P<0.02), high-sensitivity tumor necrosis factor-α (−13.6% P<0.01), and interleukin-6 (−18.0% P<0.01) decreased further with olmesartan and pravastatin cotherapy, but treatment with pravastatin alone (ie, cotherapy with placebo) did not significantly alter inflammation markers. Olmesartan treatment had already significantly reduced serum levels of high-sensitivity C-reactive protein (−15.1% P<0.05), high-sensitivity tumor necrosis factor-α (−8.9% P<0.02), interleukin-6 (−14.0% P<0.05), and monocyte chemotactic protein-1 (−6.5% P<0.01) after 6 weeks of therapy, whereas placebo treatment (ie, blood pressure reduction) had no major effect on inflammation markers. Blood pressure control was achieved with addition of hydrochlorothiazide. Pravastatin was added to the double-blind therapy at week 6 in both treatment arms. Methods and Results- We measured a panel of vascular inflammation markers, including high-sensitivity C-reactive protein, and lipid levels during 12 weeks of therapy with olmesartan (n=100) or placebo (n=99) in a prospective double-blind multicenter study. We evaluated antiinflammatory effects of the angiotensin II subtype 1 receptor antagonist olmesartan medoxomil alone and in cotherapy with the HMG-CoA reductase inhibitor pravastatin in patients with essential hypertension and microinflammation.